Role of p73 in malignancy:: tumor suppressor or oncogene?

被引:143
作者
Stiewe, T
Pützer, BM
机构
[1] Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, D-45122 Essen, Germany
[2] Univ Essen Gesamthsch, Sch Med, Inst Mol Biol, Ctr Canc Res & Canc Therapy, D-45122 Essen, Germany
关键词
p73; p53; apoptosis; tumor suppressor; oncogene;
D O I
10.1038/sj.cdd.4400995
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The recently identified p53 family member, p73, shows substantial structural and functional homology with p53. However, despite the established role of p53 as a proto-type tumor suppressor, a similar function of p73 in malignancy is questionable. Overexpression of p73 can activate typical p53-responsive genes, and activation of p73 has been implicated in apoptotic cell death induced by aberrant cell proliferation and some forms of DNA-damage. These data together with the localization of TP73 on chromosome 1p36, a region frequently deleted in a variety of human tumors, led to the hypothesis that p73 has tumor suppressor activity just like p53. However, unlike p53-/- mice, p73 knockout mice do not develop tumors. Extensive studies on primary tumor tissues have revealed overexpression of wild-type p73 in the absence of p73 mutations instead, suggesting that p73 may augment, rather than inhibit tumor development. In contrast to p53, differential splicing of the TP73 gene locus gives rise to a complex pattern of interacting p73 isoforms with antagonistic functions. In fact, induction of apoptosis by increased levels of p73 can be blocked by both p53 mutants and the N-terminally truncated p73 isoforms, which were recently shown to possess oncogenic potential. In the light of these new findings the contradictory role of p73 in malignancy will be discussed.
引用
收藏
页码:237 / 245
页数:9
相关论文
共 54 条
[1]   Mdm2 binds p73α without targeting degradation [J].
Bálint, E ;
Bates, S ;
Vousden, KH .
ONCOGENE, 1999, 18 (27) :3923-3929
[2]   Molecular alterations of p73 in human esophageal squamous cell carcinomas:: loss of heterozygosity occurs frequently;: loss of imprinting and elevation of p73 expression may be related to defective p53 [J].
Cai, YYC ;
Yang, GY ;
Nie, Y ;
Wang, LD ;
Zhao, X ;
Song, YL ;
Seril, DN ;
Liao, J ;
Xing, EP ;
Yang, CS .
CARCINOGENESIS, 2000, 21 (04) :683-689
[3]   Different p73 splicing variants are expressed in distinct tumour areas of a multifocal neuroblastoma [J].
Casciano, I ;
Ponzoni, M ;
Lo Cunsolo, C ;
Tonini, GP ;
Romani, M .
CELL DEATH AND DIFFERENTIATION, 1999, 6 (05) :391-393
[4]  
Corn PG, 1999, CANCER RES, V59, P3352
[5]   p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53 [J].
Davison, TS ;
Vagner, C ;
Kaghad, M ;
Ayed, A ;
Caput, D ;
Arrowsmith, CH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (26) :18709-18714
[6]   Additional complexity in p73:: induction by mitogens in lymphoid cells and identification of two new splicing variants ε and ζ [J].
De Laurenzi, V ;
Catani, MV ;
Terrinoni, A ;
Corazzari, M ;
Melino, G ;
Costanzo, A ;
Levrero, M ;
Knight, RA .
CELL DEATH AND DIFFERENTIATION, 1999, 6 (05) :389-390
[7]   Two new p73 splice variants, γ and δ, with different transcriptional activity [J].
De Laurenzi, V ;
Costanzo, A ;
Barcaroli, D ;
Terrinoni, A ;
Falco, M ;
Annicchiarico-Petruzzeli, M ;
Levrero, M ;
Melino, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (09) :1763-1768
[8]  
Di Como CJ, 1999, MOL CELL BIOL, V19, P1438
[9]   Wild type p73 overexpression and high-grade malignancy in breast cancer [J].
Dominguez, G ;
Silva, JM ;
Silva, J ;
Garcia, JM ;
Sanchez, A ;
Navarro, A ;
Gallego, I ;
Provencio, M ;
España, P ;
Bonilla, F .
BREAST CANCER RESEARCH AND TREATMENT, 2001, 66 (03) :183-190
[10]   Comparative analysis of p73 and p53 regulation and effector functions [J].
Fang, L ;
Lee, SW ;
Aaronson, SA .
JOURNAL OF CELL BIOLOGY, 1999, 147 (04) :823-830